Discontinuing Antidepressants in Adolescents: Special Considerations

Stopping an antidepressant in an adolescent is not a scaled-down version of the adult task. Developmental pharmacokinetics, a steep relapse curve, the FDA boxed warning for suicidality in patients under 25, and the involvement of caregivers and schools all change the calculus at the point of care. This article addresses the prescriber decisions specific to the 12–18 age band: when to stop, how to taper given the limited pediatric formulary, and how to distinguish discontinuation symptoms from relapse in a population with high baseline symptom variability.

When discontinuation is appropriate

The decision to discontinue should be driven by treatment duration, remission stability, and the index episode rather than by the patient reaching a particular age. For a first episode of pediatric major depressive disorder (MDD) that has achieved full remission, the prevailing guidance is to continue the antidepressant for 6 to 12 months after remission before attempting a taper. NICE depression guidance and the AACAP practice parameters converge on a minimum of 6 months of continuation-phase treatment past symptom resolution.

Key modifiers that argue for a longer continuation phase before any taper:

• Recurrent depression (two or more episodes): extend to 12–24 months of stability, and reconsider whether discontinuation is appropriate at all.
• Severe index episode with suicidality, psychotic features, or significant functional loss.
• Residual symptoms — partial remission predicts relapse and is a contraindication to starting a taper.
• Anxiety disorders, which tend to be chronic and relapse-prone; OCD in particular often requires multi-year treatment.

Timing the taper matters as much as the decision. Avoid discontinuing during a high-stress academic window (exam periods), during a transition between care settings (e.g., a move to college or a change of prescriber), or in the weeks before a planned loss of monitoring. The taper should occur when the adolescent has stable routines and a caregiver who can observe and report.

The relapse curve is steeper in adolescents

Relapse after antidepressant discontinuation is high across all ages, but pediatric data are particularly sobering. In the landmark Treatment for Adolescents with Depression Study (TADS) and subsequent discontinuation analyses, a substantial fraction of remitted adolescents relapsed within 6 months of stopping pharmacotherapy. Maintenance-discontinuation trials in pediatric OCD and anxiety similarly show relapse rates that frequently exceed 40–50% in the placebo (discontinued) arms within the first several months.

The clinical implication: an adolescent who has been well for only a few months is at meaningfully higher relapse risk than an adult with the same remission duration, partly because the underlying illness in youth is frequently recurrent and partly because adherence and psychosocial stressors are less stable. Document the relapse-risk discussion with both the adolescent and the caregiver before starting, and define in advance what symptom re-emergence will trigger reinstatement.

Developmental pharmacokinetics change the taper

Adolescents are not small adults pharmacokinetically. Hepatic metabolic capacity per kilogram, volume of distribution, and CYP enzyme activity differ from both younger children and adults, and they shift across puberty. Two practical consequences:

1. Half-life variability. A drug's effective half-life in a given adolescent may be shorter than the adult population value, which can produce more abrupt interdose and post-discontinuation declines in plasma concentration — and therefore more pronounced discontinuation symptoms for short-half-life agents.
2. Weight-driven dosing endpoints. The lowest commercially available tablet may represent a larger proportional dose in a lighter adolescent, making the final steps of a taper proportionally larger than intended.

Drug-specific profiles relevant to discontinuation

| Drug (generic/brand) | Approximate half-life | Active metabolite | Pediatric FDA approval | Discontinuation difficulty | ||---|---|---| | Fluoxetine (Prozac) | 4–6 days (norfluoxetine 4–16 days) | Yes (norfluoxetine) | MDD ≥8 yrs; OCD ≥7 yrs | Low — self-tapering effect | | Escitalopram (Lexapro) | ~27–32 h | Minimal | MDD ≥12 yrs | Moderate | | Sertraline (Zoloft) | ~26 h | Weak (desmethylsertraline) | OCD ≥6 yrs | Moderate | | Fluvoxamine (Luvox) | ~15 h | No | OCD ≥8 yrs | Moderate–high | | Paroxetine (Paxil) | ~21 h | No | None pediatric; avoid in youth | High | | Venlafaxine (Effexor) | ~5 h (ODV ~11 h) | Yes (desvenlafaxine) | None pediatric | High | | Duloxetine (Cymbalta) | ~12 h | No | GAD ≥7 yrs | High |

The short half-life of venlafaxine, paroxetine, fluvoxamine, and duloxetine makes them the agents most associated with discontinuation symptoms in adolescents. Fluoxetine's long half-life and active metabolite provide a built-in self-taper, which is why it is sometimes used as a bridging agent when a short-half-life SSRI must be stopped.

How to taper: hyperbolic reductions adapted for the pediatric formulary

The pharmacodynamic principle established by Horowitz and Taylor (2019, Lancet Psychiatry) applies to adolescents as much as adults: serotonin transporter occupancy is a hyperbolic, not linear, function of dose. Occupancy changes little across the upper dose range and steeply across the lowest doses. Linear milligram reductions therefore produce accelerating receptor-level changes as the dose approaches zero, which is exactly where discontinuation symptoms concentrate.

Translated to practice: reductions should be proportional to the current dose, on the order of 5–10% of the current dose every 2–4 weeks, with the absolute milligram decrement shrinking as the dose falls. The final steps before zero are the smallest. The Maudsley Deprescribing Guidelines (Horowitz & Taylor, 2024) provide hyperbolic dose-reduction schedules built on this principle.

The obstacle in pediatrics is formulation. The available solid-dose strengths often do not permit the small final steps a hyperbolic taper requires. Options:

• Liquid formulations. Fluoxetine, sertraline, escitalopram, and paroxetine are available as oral solutions in many markets, allowing precise sub-tablet dosing for the final phase. This is the cleanest route to a true hyperbolic taper in an adolescent.
• Dispersible/dissolvable preparations measured in water to achieve fractional doses.
• Tablet splitting for the higher dose range only — acknowledge that splitting is imprecise and is not adequate for the lowest steps.
• Alternate-day dosing is not recommended for short-half-life agents (it produces large peak-to-trough swings and intermittent withdrawal), though it is acceptable for fluoxetine because of its long half-life.

A representative escitalopram taper from 10 mg in an adolescent, using the oral solution for the final steps, might run: 10 → 7.5 → 5 → 3.5 → 2.5 → 1.5 → 1 → 0.5 → stop, with 2–4 weeks at each step and slower steps near the end if symptoms emerge. The specific decrements are illustrative; the principle is proportional reduction with the smallest steps last.

Distinguishing discontinuation symptoms from relapse

This differential is the single most consequential judgment in pediatric antidepressant discontinuation, and it is harder in adolescents because mood lability is developmentally normal and self-report is less reliable.

Feature	Discontinuation symptoms	Relapse of depression/anxiety
Onset after dose reduction	Days (typically 1–4)	Weeks to months
Time course	Transient; resolves over 1–3 weeks	Progressive; worsens or persists
Hallmark symptoms	Dizziness, "brain zaps," nausea, flu-like malaise, vivid dreams, irritability	Anhedonia, low mood, hopelessness, social withdrawal, cognitive symptoms
Response to dose reinstatement	Rapid (often within 24–72 h)	Slow (weeks)
Relationship to taper steps	Tightly time-locked to reductions	Independent of taper timing

The FINISH mnemonic (Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, Hyperarousal) captures the discontinuation syndrome and is a useful teaching tool for caregivers. The decisive test is time-locking and reinstatement response: symptoms that appear within days of a reduction and resolve quickly when the prior dose is reinstated are discontinuation phenomena, not relapse. Symptoms that emerge weeks later, are dominated by mood and cognition, and do not respond promptly to reinstatement should be treated as relapse.

When the picture is genuinely ambiguous, the lower-risk move is to hold or reinstate the last effective dose, stabilize, and resume the taper more slowly — rather than pushing through and risking an unrecognized relapse in a population where relapse can carry suicide risk.

Suicidality monitoring during and after discontinuation

The FDA boxed warning for increased suicidal ideation and behavior in patients under 25 frames the entire discontinuation process. Two periods of elevated vigilance apply:

1. Early in any dose change, including reductions, the boxed-warning logic for close monitoring applies — not only to initiation and dose increases.
2. The post-discontinuation relapse window, where re-emerging depression itself carries suicide risk.

Practical monitoring: schedule contact at a cadence matched to the taper (e.g., a check at each dose reduction, and within 1–2 weeks of the final step), use a structured measure such as the PHQ-A or the Columbia-Suicide Severity Rating Scale (C-SSRS) at each touchpoint, and ensure the caregiver knows specific warning signs and how to escalate. Do not discontinue an antidepressant in an adolescent without a defined safety plan and a named contact for deterioration.

Involving caregivers and the care system

Adolescent discontinuation is a three-party process (clinician, adolescent, caregiver), and increasingly a four-party one when a school counselor or therapist is involved. Concrete steps:

• Brief the caregiver on the FINISH symptom set and the discontinuation-versus-relapse distinction so they can report accurately rather than alarmingly.
• Engage the adolescent directly in the decision where developmentally appropriate; perceived autonomy improves adherence to the taper schedule and to follow-up.
• Coordinate with concurrent psychotherapy. Continuing CBT or IPT-A through the taper reduces relapse risk and gives the adolescent non-pharmacological tools as the medication is withdrawn. Do not taper medication and end therapy simultaneously.
• Plan around care transitions. If the adolescent is moving to a new prescriber or to a college health system, complete the taper before the handoff or explicitly transfer the taper plan in writing.

Clinical pearls

• Do not start a taper from partial remission. Residual symptoms predict relapse; achieve full remission and 6–12 months of stability first (longer for recurrent or anxiety-spectrum illness).
• Use the oral solution for the final steps. Pediatric solid-dose strengths rarely permit the small hyperbolic reductions that matter most; liquid formulations of fluoxetine, sertraline, escitalopram, or paroxetine make a true 5–10% proportional taper feasible.
• Reductions should be proportional, with the smallest absolute decrements last — roughly 5–10% of current dose every 2–4 weeks, per the hyperbolic-tapering principle (Horowitz & Taylor, 2019).
• Time-lock and reinstatement are your differential. Symptoms within days of a reduction that resolve on reinstatement are discontinuation; mood-dominant symptoms emerging weeks later that do not respond to reinstatement are relapse.
• Treat every dose change as a boxed-warning event. Apply C-SSRS or PHQ-A monitoring at each reduction and through the post-discontinuation relapse window, with a written safety plan.
• Avoid paroxetine and short-half-life SNRIs in youth where alternatives exist, and never stop them abruptly; bridge to fluoxetine if a short-half-life agent must be discontinued and symptoms are intolerable.
• Do not withdraw medication and psychotherapy at the same time. Keep psychotherapeutic support running through and beyond the taper.

---

For more clinician resources on safe deprescribing and tapering, visit tapermeds.com.